Minapharm Pharmaceuticals results, Q2 2025
Net profit, assets, equity and cash flow for Q2 2025, against the same period a year earlier, from the published financial statements.
Net profit39.96 millionEGP · −74.6% vs the same period a year earlier
Operating cash flow379 millionEGP · +70.9% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q2 2025 was about 39.96 million EGP, down −74.6% from 157 million EGP in Q2 2024.
- Operating cash flow for Q2 2025 was positive at 379 million EGP.
Key lines against the same period a year earlier
This periodQ2 2024Change
Net profit39.96 million157 million−74.6%
Gross profit773 million917 million−15.7%
Total assets—12 billion—
Total liabilities—7.59 billion—
Shareholders' equity—4.41 billion—
Total liabilities and equity—12 billion—
Operating cash flow379 million222 million+70.9%
Investing cash flow-187 million-574 million+67.4%
Financing cash flow108 million1.32 billion−91.8%
Net change in cash300 million964 million−68.9%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy